TLSA earnings

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Tiziana is also hosting a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS. Ivor Elrifi, Chief Executi

Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168)Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and tolerability profile at both doses studiedClinically meaningful and statistically significant fatigue improvements in both dose arms after only 12 weeks underscore the strong therapeutic potential of nasal foralumab in a population with no FDA-approved therapies for na-SPMS BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead

NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)